Years of Potential Life Lost and Productivity Costs Because of Cancer Mortality and for Specific Cancer Sites Where Human Papillomavirus May Be a Risk Factor for Carcinogenesis-United States, 2003
Years of Potential Life Lost and Productivity Costs Because of Cancer Mortality and for Specific Cancer Sites Where Human Papillomavirus May Be a Risk Factor for Carcinogenesis-United States, 2003
复制标题
DOI：
10.1002/cncr.23761
复制
发表时间：
2008-11-15
期刊：
影响因子：
6.2
通讯作者：
Balamurugan, Appathurai
中科院分区：
文献类型：
--
作者：
Ekwueme, Donatus U.;Chesson, Harrell W.;Balamurugan, Appathurai
背景虽然潜在寿命损失年数（YPLL）和死亡率相关的生产力成本构成了人类乳头瘤病毒（HPV）可能是致癌风险因素的癌症（本报告中称为HPV相关癌症）负担的很大一部分，但对这些成本的估计是有限的。作者估计了2003年美国HPV相关癌症（不考虑这些癌症中每种可归因于HPV的百分比）和所有恶性癌症的死亡率相关负担（根据YPLL和生产成本）。作者使用2003年全国死亡率数据和美国寿命表来估计HPV相关癌症和所有恶性癌症的YPLL。用预期寿命法估计YPLL。人力资本方法用于估计HPV相关癌症和所有恶性癌症导致的过早死亡所造成的预期未来终生生产力损失的价值。间接死亡成本估计为死亡人数和个人未来收入预期值的乘积，包括家务服务的估算值。在2003年，HPV相关癌症占181，026 YPLL，占美国所有恶性癌症估计750万YPLL的2.4%。每例HPV相关癌症死亡的平均YPLL数为21.8，每例恶性癌症死亡的平均YPLL数为16.3。总体而言，HPV相关癌症对30至34岁女性的YPLL的相对贡献最大。2003年，HPV相关癌症死亡率的终身生产力成本为37亿美元，总体恶性癌症死亡率为1335亿美元。HPV相关癌症在过早死亡和生产力损失方面造成了相当大的负担。Cancer 2008;113（10 suppl）：2936-45. 2008年由美国癌症协会出版。
BACKGROUND. Although years of potential life lost (YPLL) and mortality-related productivity costs comprise a substantial portion of the burden of cancers where human papillomavirus (HPV) may be a risk factor for carcinogenesis (called HPV-associated cancers in this report), estimates of these costs are limited. The authors estimated the mortality-related burden (in terms of YPLL and productivity costs) of HPV-associated cancers (without regard to the percentage of each of these cancers that could be attributed to HPV) and all malignant cancers in the United States in 2003.METHODS. The authors used 2003 national mortality data and US life tables to estimate YPLL for HPV-associated cancers and all malignant cancers. YPLL was estimated by using the life expectancy method. The human capital approach was used to estimate the value of the expected future lifetime productivity losses caused by premature deaths from HPV-associated cancers and all malignant cancers. Indirect mortality costs were estimated as the product of the number of deaths and the expected value of individuals' future earnings, including an imputed value of housekeeping services.RESULTS. In 2003, HPV-associated cancers accounted for 181,026 YPLL, which represented 2.4% of the estimated 7.5 million YPLL attributable to all malignant cancers in the United States. The average number of YPLL was 21.8 per HPV-associated cancer death and 16.3 per death from overall malignant cancers. Overall, HPV-associated cancers had the largest relative contribution to YPLL in women ages 30 to 34 years. The lifetime productivity cost from mortality in 2003 was $3.7 billion for HPV-associated cancer mortality and $133.5 billion for overall malignant cancer mortality.CONCLUSIONS. HPV-associated cancers impose a considerable burden in terms of premature deaths and productivity losses. Cancer 2008;113(10 suppl):2936-45. Published 2008 by the American Cancer Society.*